Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group

Journal of Clinical Oncology

Volumn 26, Issue 7, 2008, Pages 1033-1039

  De Palma, Rossana ^a   Liberati, Alessandro ^a   Ciccone, Giovannino ^a   Bandieri, Elena ^a   Belfiglio, Maurizio ^a   Ceccarelli, Manuela ^a   Leoni, Maurizio ^a   Longo, Giuseppe ^a   Magrini, Nicola ^a   Marangolo, Maurizio ^a   Roila, Fausto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; COLORECTAL CANCER; DECISION MAKING; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LUNG CANCER; MALE; PRIORITY JOURNAL; QUALITY CONTROL; QUESTIONNAIRE; RISK BENEFIT ANALYSIS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COLORECTAL TUMOR; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; PRACTICE GUIDELINE; RISK; RISK ASSESSMENT; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 41949133052     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.1608     Document Type: Article

References (34)

1. Gabbay J, Walley T: Introducing new health interventions. BMJ 332:64-65, 2006
2. Stevens A, Milne R: Health technology assessment in England and Wales. Int J Technol Assess Health Care 20:11-24, 2004
3. McDonnell A, Wilson R: Evaluating and implementing new services. BMJ 332:109-112, 2006
4. De Palma R, Liberati A: Il Programma Ricerca e Innovazione della Regione Emiliaqqhyphen Romagna (PRI ER): Un approccio nello sviluppo della ricerca nel e per il servizio sanitario. Techne 10:171-174, 2006
5. Roberts TG, Chabner BA: Beyond fast track for drug approvals. N Engl J Med 351:501-505, 2004
6. Wood AJJ: A proposal for radical changes in the drug-approval process. N Engl J Med 355:618-623, 2006
7. Avorn J: FDA standards: Good enough for government work? N Engl J Med 353:969-972, 2005
8. Garattini S, Bertelè V: Efficacy, safety and cost of new anticancer drugs. BMJ 325:269-271, 2002
9. Cancer Care Ontario Program: Chemotherapy Regimens: Breast Adjuvant. http://www.cancercare.on.ca/index_chemoRegimensbyDisease.htm
10. Browman GP, Levine MN, Mohide EA, et al: The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation. J Clin Oncol 13:502-512, 1995
11. Pater JL, Browman GP, Brouwers MC, et al: Funding new cancer drugs in Ontario: Closing the loop in the practice guidelines development cycle. J Clin Oncol 19:3392-3396, 2001
12. Atkins D, Best D, Briss PA, et al: Grading quality of evidence and strength of recommendations: A new method by the GRADE Working Group. BMJ 328:1490, 2004
13. Schünemann HJ, Jaeschke J, Cook D, et al: An official ATS statement: Grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 174:605-614, 2006
14. Schünemann HJ, Hill S, Kakad M, et al: Transparent development of the WHO rapid advice guidelines. PLoS Medicine 4:e119, 2007
15. Programma Ricerca e Innovazione Emilia Romagna (PRI-ER): Area di programma Ricerca e Innovazione: I progetti. http://asr.regione.emilia-romagna. it/wcm/asr/eventi/20050223_ws2_prier.htm
16. Programma Ricerca e Innovazione Emilia Romagna (PRI-ER): Raccomandazioni sulla terapia adiuvante del tumore della mammella, del colon retto e del polmone. http://asr.regione.emilia-romagna.it/wcm/asr/ric_inn/prier/gr_v/ pr_oncologia/stpr_farmaci_onco/raccomandazione.htm
17. Grilli R, Taroni F: Managing the introduction of expensive medical procedures: Use of a registry. J Health Serv Res Policy 11:89-93, 2006
18. Programma Ricerca e Innovazione Emilia Romagna (PRI-ER): Pubblicazioni: L'innovazione in radioterapia: trattamenti più brevi ma ugualmente efficaci per il tumore del seno? http://asr.regione.emilia-romagna.it/wcm/asr/ collana_pillole/pill025/link/pill25.pdf
19. Programma Ricerca e Innovazione Emilia Romagna (PRI-ER): Pubblicazioni: Impatto diagnostico della Tomografia Computerizzata multistrato nella malattia coronaria. http://asr.regione.emilia-romagna.it/wcm/asr/collana_pillole/pill027/ link/pill27.pdf
20. Programma Ricerca e Innovazione Emilia Romagna (PRI-ER): Pubblicazioni: Le indicazioni all'uso appropriato della PET in oncologia:uno strumento per il governo clinico. http://asr.regione.emilia-romagna.it/wcm/asr/collana_pillole/ pill029/link/pill29.pdf
21. Programma Ricerca e Innovazione Emilia Romagna (PRI-ER): Pubblicazioni: Cosa devono fare i pazienti dopo le cure iniziali? Un progetto per l'appropriatezza del Follow-up in oncologia. http://asr.regione.emilia-romagna. it/wcm/asr/collana_pillole/pill026/link/pill26.pdf
22. Italian Drug Agency (AIFA): http://www.agenziafarmaco.it/section8983.html
23. Barrett A, Roques T, Small M, et al: How much will Herceptin really cost? BMJ 333:1118-1120, 2006
24. National Institute for Health and Clinical Excellence: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. Tech Appraisal Guidance 107:1-16, 2006
25. Trudeau M, Madarnas Y, McCready D, et al: The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/neu-overexpressing breast cancer: A clinical practice guideline. Cancer Care Ontario Program 1:1-5, 2007
26. Jonker D, Rumble RB, Maroun J, et al: The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first and second-line treatment of advanced colorectal cancer: A clinical practice guideline. Cancer Care Ontario Program 1:1-4, 2005
27. National Institute for Health and Clinical Excellence: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. Tech Appraisal Guidance 112:1-37, 2006
28. Herrin J, Etchason JA, Kahan JP, et al: Effect of panel composition on physician ratings appropriateness of abdominal aortic aneurysm surgery: Elucidating differences between multispecialty panel results and specialty society recommendations. Health Policy 42:67-81, 1997
29. Kravitz RL, Park RE, Kahan JP: Measuring the clinical consistency of panelists' appropriateness ratings: The case of coronary artery bypass surgery. Health Policy 42:135-143, 1997
30. Liberati A, Apolone G, Nicolucci A, et al: The role of attitudes, beliefs and personal characteristics of Italian physicians in the surgical treatment of early breast cancer. Am J Public Health 81:38-42, 1991
31. Fitch K, Lazaro P, Aguilar MD, et al: Physicians recommendation for coronary revascularisation: Variations by clinical specialty. Eur J Publ Health 9:181-187, 1999
32. Ayanian JZ, Laundrum MB, Normand SL, et al: Rating the appropriateness of coronary angiography: Do practicing physicians agree with an export panel and with each other? N Engl J Med 338:1896-1904, 1998
33. Choudhry NK, Stelfox HT, Detsky S: Relationship between authors of clinical practice guidelines and industry. JAMA 287:612-617, 2002
34. Frye CB: Disclosing conflicts of interests involving clinicians who prepare therapeutic guidelines. Am J Health Syst Pharm 62:361-362, 2005